288 related articles for article (PubMed ID: 17510417)
1. Molecular basis of the synergistic antiangiogenic activity of bevacizumab and mithramycin A.
Jia Z; Zhang J; Wei D; Wang L; Yuan P; Le X; Li Q; Yao J; Xie K
Cancer Res; 2007 May; 67(10):4878-85. PubMed ID: 17510417
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic inhibition of Sp1 expression in growing tumors by mithramycin a correlates directly with potent antiangiogenic effects on human pancreatic cancer.
Yuan P; Wang L; Wei D; Zhang J; Jia Z; Li Q; Le X; Wang H; Yao J; Xie K
Cancer; 2007 Dec; 110(12):2682-90. PubMed ID: 17973266
[TBL] [Abstract][Full Text] [Related]
3. Targeted inhibition of Sp1-mediated transcription for antiangiogenic therapy of metastatic human gastric cancer in orthotopic nude mouse models.
Wang L; Guan X; Zhang J; Jia Z; Wei D; Li Q; Yao J; Xie K
Int J Oncol; 2008 Jul; 33(1):161-7. PubMed ID: 18575762
[TBL] [Abstract][Full Text] [Related]
4. Combining betulinic acid and mithramycin a effectively suppresses pancreatic cancer by inhibiting proliferation, invasion, and angiogenesis.
Gao Y; Jia Z; Kong X; Li Q; Chang DZ; Wei D; Le X; Suyun H; Huang S; Wang L; Xie K
Cancer Res; 2011 Aug; 71(15):5182-93. PubMed ID: 21673052
[TBL] [Abstract][Full Text] [Related]
5. A study of the suppressive effect on human pancreatic adenocarcinoma cell proliferation and angiogenesis by stable plasmid-based siRNA silencing of c-Src gene expression.
Zhao X; Li DC; Zhao H; Li Z; Wang JX; Zhu DM; Zhou J; Cen JN
Oncol Rep; 2012 Mar; 27(3):628-36. PubMed ID: 22200682
[TBL] [Abstract][Full Text] [Related]
6. Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity.
Wei D; Wang L; He Y; Xiong HQ; Abbruzzese JL; Xie K
Cancer Res; 2004 Mar; 64(6):2030-8. PubMed ID: 15026340
[TBL] [Abstract][Full Text] [Related]
7. Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma.
Shi Q; Le X; Abbruzzese JL; Peng Z; Qian CN; Tang H; Xiong Q; Wang B; Li XC; Xie K
Cancer Res; 2001 May; 61(10):4143-54. PubMed ID: 11358838
[TBL] [Abstract][Full Text] [Related]
8. Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts.
Holloway SE; Beck AW; Shivakumar L; Shih J; Fleming JB; Brekken RA
Ann Surg Oncol; 2006 Aug; 13(8):1145-55. PubMed ID: 16791450
[TBL] [Abstract][Full Text] [Related]
9. Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity.
Jia Z; Gao Y; Wang L; Li Q; Zhang J; Le X; Wei D; Yao JC; Chang DZ; Huang S; Xie K
Cancer Res; 2010 Feb; 70(3):1111-9. PubMed ID: 20086170
[TBL] [Abstract][Full Text] [Related]
10. Effect of bevacizumab, a humanized monoclonal antibody to vascular endothelial growth factor, on peritoneal metastasis of MNK-45P human gastric cancer in mice.
Ninomiya S; Inomata M; Tajima M; Ali AT; Ueda Y; Shiraishi N; Kitano S
J Surg Res; 2009 Jun; 154(2):196-202. PubMed ID: 19329124
[TBL] [Abstract][Full Text] [Related]
11. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
12. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.
Ciardiello F; Bianco R; Damiano V; Fontanini G; Caputo R; Pomatico G; De Placido S; Bianco AR; Mendelsohn J; Tortora G
Clin Cancer Res; 2000 Sep; 6(9):3739-47. PubMed ID: 10999768
[TBL] [Abstract][Full Text] [Related]
13. Insulin-like growth factor-I receptor blockade reduces tumor angiogenesis and enhances the effects of bevacizumab for a human gastric cancer cell line, MKN45.
Li H; Adachi Y; Yamamoto H; Min Y; Ohashi H; Ii M; Arimura Y; Endo T; Lee CT; Carbone DP; Imai K; Shinomura Y
Cancer; 2011 Jul; 117(14):3135-47. PubMed ID: 21264842
[TBL] [Abstract][Full Text] [Related]
14. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor.
Gerber HP; Kowalski J; Sherman D; Eberhard DA; Ferrara N
Cancer Res; 2000 Nov; 60(22):6253-8. PubMed ID: 11103779
[TBL] [Abstract][Full Text] [Related]
15. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy.
Lucio-Eterovic AK; Piao Y; de Groot JF
Clin Cancer Res; 2009 Jul; 15(14):4589-99. PubMed ID: 19567589
[TBL] [Abstract][Full Text] [Related]
16. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
17. Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors.
Zhang J; Jia Z; Li Q; Wang L; Rashid A; Zhu Z; Evans DB; Vauthey JN; Xie K; Yao JC
Cancer; 2007 Apr; 109(8):1478-86. PubMed ID: 17340592
[TBL] [Abstract][Full Text] [Related]
18. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.
Miyazaki S; Kikuchi H; Iino I; Uehara T; Setoguchi T; Fujita T; Hiramatsu Y; Ohta M; Kamiya K; Kitagawa K; Kitagawa M; Baba S; Konno H
Int J Cancer; 2014 Jul; 135(2):295-307. PubMed ID: 24375080
[TBL] [Abstract][Full Text] [Related]
19. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
[TBL] [Abstract][Full Text] [Related]
20. [Impacts of Bevacizumab on vascular endothelial growth factor and Sp1 expression in gastric cancer xenografts].
Zhou CF; Ji J; Yuan F; Yu YY; Liu BY; Zhang J; Zhu ZG
Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Feb; 15(2):180-4. PubMed ID: 22368029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
